Concepedia

S. Tries

ST

Statistics

Publications

12

Citations

530

H-Index

12

Active since

1994

Affiliations

Merck KGaA, Darmstadt (Germany)(Current)

University of Tübingen

Hôpital Notre-Dame

S. Tries is an author at Merck KGaA, Darmstadt (Germany) specializing in pharmacology, medicine, and medicinal chemistry.

Publications per year

1994–2002

12

Publications

12

In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: Suppression of collagenase 1 and interleukin-1? synthesis

Dragan Jovanović, Julio Fernandes, Johanne Martel-Pelletier et al. · Arthritis & Rheumatism · 2001 · 104 citations · Full text

, , +17

The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2

S. Tries, W. Neupert, Stefan Laufer · Inflammation Research · 2002 · 97 citations

, , +9

The pharmacological profile of ML3000: A new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase

S. Tries, Stefan Laufer · Inflammopharmacology · 2001 · 72 citations

, , +7

ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury

John L. Wallace, L. Carter, W. McKnight et al. · European Journal of Pharmacology · 1994 · 48 citations

, , +12

Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors.

Christelle Boileau, Johanne Martel‐Pelletier, Jean‐Yves Jouzeau et al. · PubMed · 2002 · 39 citations

, , +17

1–5 of 12